Takeda Laxative Wins U.S. Approval for Adults
02/18/06 01:36 PM
Edit
Reply
Quote
Takeda Laxative Wins U.S. Approval for Adults
WASHINGTON (Reuters) Jan 31 - U.S. health officials said on Tuesday that they approved a new prescription drug, called Amitiza, to treat adults with chronic constipation.
The drug, made by Japan's Takeda Pharmaceutical Co. Ltd. and privately held Sucampo Pharmaceuticals Inc., helps relieve constipation, abdominal bloating and discomfort, the Food and Drug Administration said in a statement.
It is intended for patients who experience constipation over time with no known cause, the agency said.
The new capsules work by increasing fluids in the intestines and should be taken twice daily with food.
Side effects can include headache, nausea, diarrhea and abdominal pain, among others, the FDA said.
The drug should be taken twice daily with food to help increase fluids in the intestines, the Food and Drug Administration said in a statement.
-------------------- Heather is the Administrator of the IBS Message Boards. She’s the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!
LEGAL DISCLAIMER - This website is not intended to replace the services of a physician, nor does it constitute a doctor-patient relationship. Information on this web site is provided for informational purposes only and is not a substitute for professional medical advice. You should not use the information on this web site for diagnosing or treating a medical or health condition. If you have or suspect you have an urgent medical problem, promptly contact your professional healthcare provider.
Any application of the recommendations in this website is at the reader's discretion. Heather Van Vorous, HelpForIBS.com, and Heather & Company for IBS, LLC are not liable for any direct or indirect claim, loss or damage resulting from use of this website and/or any web site(s) linked to/from it. Readers should consult their own physicians concerning the recommendations on these message boards.